background
middl
east
respiratori
syndrom
mer
sever
respiratori
ill
overal
mortal
licens
proven
treatment
passiv
immunotherapi
approach
develop
prevent
treat
sever
human
medic
condit
altern
therapeut
option
absent
report
safeti
fulli
human
polyclon
igg
antibodi
produc
hyperimmun
plasma
transchromosom
cattl
immunis
mer
coronaviru
vaccin
phase
doubleblind
placebocontrol
singledos
escal
trial
nation
institut
health
clinic
center
recruit
healthi
particip
age
year
normal
laboratori
paramet
enrol
bodymass
index
creatinin
clearanc
mlmin
chronic
medic
problem
requir
daili
oral
medic
posit
rheumatoid
factor
iuml
iga
defici
mgdl
histori
allergi
intraven
immunoglobulin
human
blood
product
particip
randomli
assign
computergener
tabl
made
mask
pharmacist
one
six
cohort
contain
three
ten
particip
cohort
three
particip
randomli
assign
receiv
activ
drug
versu
normal
salin
placebo
cohort
six
particip
randomis
cohort
ten
particip
randomis
particip
receiv
mgkg
mgkg
mgkg
mgkg
mgkg
mgkg
equival
volum
placebo
salin
control
day
follow
clinic
laboratori
pharmacokinet
assess
day
primari
outcom
safeti
immunogen
secondari
outcom
analys
intentiontotreat
popul
trial
regist
clinicaltrialsgov
number
find
june
jan
screen
particip
elig
randomli
assign
receiv
placebo
advers
event
report
advers
event
occur
particip
receiv
mean
advers
event
per
particip
advers
event
occur
ten
particip
receiv
placebo
mean
advers
event
per
particip
common
advers
event
headach
particip
receiv
receiv
placebo
albuminuria
vs
myalgia
vs
increas
creatin
kinas
vs
common
cold
vs
one
seriou
advers
event
hospit
admiss
suicid
attempt
one
particip
receiv
mgkg
area
concentrationtim
curv
auc
mgkg
dose
day
per
ml
compar
auc
associ
efficaci
preclin
model
interpret
singl
infus
mgkg
appear
safe
well
toler
healthi
particip
human
immunoglobulin
deriv
transchromosom
cattl
could
offer
new
platform
technolog
produc
fulli
human
polyclon
igg
antibodi
medic
condit
middl
east
respiratori
syndrom
mer
sever
respiratori
ill
caus
novel
coronaviru
cov
spectrum
clinic
ill
rang
asymptomat
ill
sever
acut
respiratori
diseas
requir
intens
care
mechan
ventil
mer
overal
mortal
licens
proven
treatment
use
immun
antim
coronaviru
merscov
plasma
suggest
one
potenti
therapeut
approach
howev
difficult
collect
suffici
antimerscov
plasma
infect
patient
implement
strategi
use
passiv
immun
therapi
either
form
direct
plasma
infus
intraven
immunoglobulin
often
invok
emerg
infecti
diseas
ebola
viru
diseas
well
common
diseas
high
morbid
despit
avail
antivir
therapeut
sever
influenza
howev
use
immun
plasma
condit
similar
constraint
consist
product
larg
quantiti
antipathogenneutralis
human
plasma
immunoglobulin
requir
collect
plasma
convalesc
vaccin
human
volunt
limit
plasma
suppli
restrict
wide
implement
therapeut
one
novel
altern
method
manufactur
neutralis
intraven
antibodi
consist
high
affin
avid
use
hyperimmun
plasma
transchromosom
cattl
produc
highli
potent
antigenspecif
fulli
human
polyclon
igg
de
novo
mount
robust
antibodi
immun
respons
vaccin
develop
transchromosom
cattl
human
artifici
chromosom
construct
compris
entir
human
immunoglobulin
gene
repertoir
human
immunoglobulin
heavi
chain
igh
human
light
chain
igk
resid
two
differ
chromosom
human
be
specif
igh
locu
chromosom
igk
locu
chromosom
immunoglobulin
gene
repertoir
human
artifici
chromosom
provid
larg
divers
human
polyclon
antibodi
avoid
possibl
humanbovin
interspeci
incompat
human
protein
higm
bovin
transmembran
immunoglobulin
prebcellreceptor
complex
higm
constant
domain
partli
replac
counterpart
bovin
igm
bigm
furthermor
dna
regulatori
element
bovinis
human
artifici
chromosom
facilit
dnaprotein
interact
bovin
b
cell
human
artifici
chromosom
design
transfer
bovin
fibroblast
homozyg
tripl
knockout
two
bovin
heavychain
loci
bighm
bovin
lightchain
locu
bigl
tripleknockout
bovin
fibroblast
carri
human
artifici
chromosom
use
nuclear
donor
clone
transchromosom
cattl
merscov
spike
protein
attach
hostcel
receptor
also
known
dipeptidyl
peptidas
mediat
subsequ
cell
fusion
vaccin
mice
plasmid
vaccin
express
spike
glycoprotein
show
gener
neutralis
antibodi
block
receptor
bind
nonreceptorbind
domain
seroconvers
spike
protein
measur
igg
associ
resolut
clinic
ill
patient
merscov
infect
level
antispik
igg
invers
correl
lower
respiratori
tract
viral
load
reason
purifi
alhasa
strain
merscov
spike
protein
nanoparticl
clade
b
strain
manufactur
novavax
inc
gaithersburg
md
usa
chosen
immunogen
gener
antimerscov
intraven
immunoglobulin
transchromosom
bovin
system
thereaft
known
purpos
phase
studi
evalu
safeti
toler
pharmacokinet
singl
infus
healthi
adult
trial
repres
firstinhuman
clinic
studi
use
fulli
human
antibodi
deriv
transchromosom
cattl
doubleblind
placebocontrol
singledos
escal
phase
randomis
control
trial
nation
institut
health
nih
clinic
center
bethesda
md
studi
conduct
accord
applic
regulatori
intern
confer
harmonizationgood
clinic
practic
requir
studi
protocol
approv
nation
institut
allergi
infecti
diseas
institut
review
board
protocol
evid
studi
search
pubm
oct
studi
use
search
term
titl
abstract
middl
east
respiratori
syndrom
mer
antivir
treatment
restrict
articl
type
clinic
trial
speci
human
languag
restrict
found
articl
remov
search
restrict
titl
abstract
term
remov
speci
restrict
human
be
exclud
studi
assess
mer
therapeut
rather
mention
background
discuss
found
previou
public
mer
therapeut
human
be
addit
search
studi
use
search
term
intraven
immunoglobulin
igiv
bovin
cow
restrict
articl
type
clinic
trial
speci
human
exclud
studi
assess
bovin
intraven
immunoglobulin
identifi
previou
public
mer
therapeut
human
knowledg
first
studi
show
safeti
toler
pharmacokinet
intraven
immunoglobulin
deriv
transchromosom
cattl
first
studi
describ
safeti
put
therapeut
specif
mer
evid
studi
show
singl
infus
mgkg
appear
safe
well
toler
healthi
particip
consid
investig
treatment
mer
elig
particip
healthi
adult
men
women
age
year
bodymass
index
creatinin
clearanc
mlmin
calcul
use
chronic
kidney
diseas
epidemiolog
collabor
formula
particip
requir
normal
laboratori
paramet
enrol
could
chronic
medic
problem
requir
daili
oral
medic
posit
rheumatoid
factor
defin
rheumatoid
factor
iuml
iga
defici
defin
iga
mgdl
histori
allergi
intraven
immunoglobulin
human
blood
product
particip
requir
use
two
effect
form
contracept
least
one
barrier
method
full
list
exclus
criteria
includ
appendix
particip
provid
written
inform
consent
screen
unmask
pharmacist
nih
clinic
center
pharmaci
gener
blind
randomis
scheme
studi
initi
screen
studi
particip
enrol
sequenti
one
six
cohort
day
studi
drug
dose
unmask
pharmacist
determin
treatment
alloc
refer
next
posit
randomis
scheme
cohort
three
particip
randomli
assign
receiv
activ
drug
versu
normal
salin
placebo
cohort
six
particip
randomli
assign
cohort
ten
particip
randomli
assign
studi
particip
studi
team
member
remain
mask
throughout
entir
studi
studi
treatment
provid
infus
bag
content
obscur
opaqu
cover
bag
tube
manufactur
sab
biotherapeut
inc
sioux
fall
sd
usa
two
transchromosom
bovin
hyperimmunis
purifi
alhasa
strain
merscov
protein
nanoparticl
novavax
inc
mgkg
formul
sab
proprietari
adjuv
formul
transchromosom
cattl
vaccin
five
time
interv
hyperimmun
plasma
bodyweight
collect
transchromosom
cow
day
day
third
fourth
fifth
vaccin
plasma
store
use
addit
manufactur
method
detail
appendix
suppli
vial
contain
mg
per
ml
lot
use
elisa
bind
titr
umg
assay
abil
neutralis
merscov
vitro
use
fluorescencereduct
neutralis
assay
vero
cell
concentr
inhibit
rel
fluoresc
intens
observ
dose
use
six
cohort
mgkg
cohort
prepar
concentr
mgml
normal
salin
mgkg
cohort
prepar
mgml
mgkg
cohort
prepar
mgml
mgkg
cohort
prepar
mgml
mgkg
cohort
prepar
mgml
mgkg
cohort
prepar
mgml
particip
randomli
assign
placebo
receiv
normal
salin
control
volum
equival
receiv
activ
drug
infus
start
rate
mlkg
per
h
escal
mlkg
per
h
increment
everi
min
maximum
rate
mlkg
per
h
depend
cohort
highest
dose
cohort
maximum
infus
rate
mgkg
per
h
infus
less
tenth
maximum
rate
standard
intraven
immunoglobulin
per
administr
guidelin
nih
clinic
center
maximum
mgkg
per
h
start
dose
mgkg
lower
maximum
preclin
anim
toxic
studi
dose
mgkg
target
dose
mgkg
exce
effect
dose
preclin
model
lower
maximum
nonclin
dose
sab
biotherapeut
inc
unpublish
particip
screen
week
dose
vital
sign
obtain
start
infus
approxim
min
start
infus
everi
min
thereaft
end
infus
everi
h
h
infus
particip
seen
day
blood
sampl
pharmacokinet
analysi
obtain
baselin
h
end
infus
h
end
infus
day
studi
visit
particip
question
new
symptom
medic
condit
new
medic
new
symptom
abnorm
laboratori
result
captur
advers
event
test
serum
pharmacokinet
use
elisa
assay
function
inhibit
pharmacodynam
use
mer
microneutralis
assay
assess
immunogen
test
antiigg
antibodi
use
rheumatoid
factor
antidrug
antibodi
antibovin
antibodi
anticamelid
antibodi
antibodi
use
manufactur
process
appendix
primari
outcom
safetyi
type
frequenc
advers
event
experienc
particip
receiv
compar
placebo
secondari
outcom
pharmacokinet
profil
mer
viru
neutralis
assay
time
pharmacodynam
immunogen
determin
studi
sampl
size
detect
advers
event
true
rate
probabl
cohort
larger
dose
cohort
wherea
see
onlin
appendix
rarer
event
true
rate
could
detect
probabl
analysi
intentiontotreat
popul
imput
miss
data
analys
pharmacokinet
data
use
phoenix
winnonlin
softwar
version
cetara
st
loui
mo
noncompartment
analysi
compartment
model
drug
serum
key
noncompartment
analysi
pharmacokinet
paramet
interest
includ
maximum
observ
concentr
c
max
appar
elimin
rate
constant
z
determin
calcul
absolut
valu
slope
loglinear
regress
plasma
concentrationtim
plot
minimum
three
concentr
along
termin
phase
elimin
halflif
calcul
z
area
concentrationtim
curv
auc
h
last
pharmacokinet
sampl
postdos
auc
last
infin
auc
calcul
linearup
logdown
trapezoid
rule
clearanc
calcul
doseauc
volum
distribut
calcul
dose
auc
last
z
calcul
geometr
mean
ratio
ci
compar
pharmacokinet
paramet
cohort
assess
dose
linear
proportion
test
structur
model
one
two
three
compart
determin
good
fit
compartment
model
visual
inspect
plot
observ
predict
concentr
versu
time
weight
residu
versu
predict
concentr
pharmacokinet
paramet
coeffici
variat
akaik
inform
criteria
twocompart
model
select
parameteris
term
central
compart
clearanc
central
compart
volum
distribut
intercompartment
clearanc
peripher
volum
distribut
secondari
paramet
distribut
elimin
rate
distribut
halflif
plot
reciproc
highest
neutralis
titr
time
use
calcul
auc
last
assess
correl
neutralis
titr
auc
last
auc
last
use
linear
regress
trial
regist
clinicaltrialsgov
number
employe
sponsor
studi
involv
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
june
jan
screen
particip
studi
sequenti
randomli
assign
six
cohort
figur
studi
end
fulli
enrol
alloc
studi
group
particip
complet
plan
followup
baselin
characterist
randomli
assign
particip
shown
tabl
advers
event
report
occur
particip
receiv
mean
advers
event
per
particip
advers
event
occur
ten
particip
receiv
placebo
mean
advers
event
per
particip
tabl
one
grade
advers
event
depress
one
grade
advers
event
suicid
attempt
occur
particip
one
seriou
advers
event
hospit
admiss
suicid
attempt
particip
receiv
mgkg
two
advers
event
particip
judg
unrel
studi
intervent
particip
histori
depress
sever
year
disclos
time
screen
particip
receiv
medic
care
treatment
time
enrol
common
advers
event
headach
albuminuria
increas
creatin
kinas
common
cold
myalgia
low
serum
bicarbon
advers
event
note
similar
proport
receiv
placebo
tabl
two
hypotens
event
occur
studi
drug
administr
cohort
mgkg
one
particip
receiv
one
receiv
placebo
regard
hypotens
event
particip
receiv
min
start
infus
particip
complain
feel
warm
slightli
letharg
blood
pressur
time
mm
hg
lower
preinfus
increas
heart
rate
infus
stop
min
intervent
hypotens
resolv
infus
restart
episod
hypotens
low
serum
bicarbon
seen
particip
receiv
three
note
cohort
mgkg
mgkg
two
vasovag
reaction
occur
particip
assign
receiv
doseproport
increas
paramet
c
max
auc
rang
dose
mgkg
mgkg
tabl
use
pharmacokinet
data
mgkg
cohort
termin
phase
could
identifi
multipl
concentr
limit
assay
detect
mean
concentr
versu
time
profil
cohort
dose
shown
figur
concentr
infus
appear
follow
biexponenti
declin
best
fit
twocompartment
pharmacokinet
model
result
key
pharmacokinet
paramet
noncompartment
analysi
shown
tabl
paramet
obtain
twocompartment
model
present
appendix
averag
termin
elimin
halflif
within
rang
typic
antibodi
human
be
approxim
day
across
dose
cohort
exclud
mgkg
cohort
uncorrect
baselineadjust
serum
immunoglobulin
concentr
time
appear
correl
dose
administ
pharmacokinet
concentr
data
shown
determin
antim
neutralis
antibodi
titr
use
strain
merscov
clade
strain
microneutralis
titr
correl
concentr
serum
figur
function
neutralis
mer
viru
seem
follow
pharmacokinet
exposur
describ
previous
p
pharmacodynam
analysi
use
microneutralis
titr
show
similar
result
geometr
mean
titr
mgkg
cohort
day
day
appendix
investig
immunogen
sever
way
assess
presenc
antiigg
antibodi
use
rheumatoid
factor
one
particip
cohort
mgkg
becam
rheumatoidfactor
posit
day
maximum
rheumatoid
factor
iuml
posit
rhematoid
factor
persist
throughout
studi
associ
symptom
find
advers
event
report
particip
albuminuria
also
assess
antidrug
antibodi
three
particip
antidrug
antibodi
present
baselin
studi
drug
administr
persist
chang
throughout
studi
one
particip
mgkg
cohort
two
mgkg
cohort
pharmacokinet
paramet
three
particip
compar
particip
respect
cohort
signific
differ
c
max
auc
particip
preexist
higher
result
auc
cohort
geometr
mean
new
antidrug
antibodi
develop
administr
assess
presenc
antibovin
light
chain
repres
residu
bovin
protein
might
present
final
intraven
immunoglobulin
product
seven
particip
antibodi
bovin
light
chain
detect
baselin
develop
new
antibovin
antibodi
administr
also
assess
whether
anticamelid
antibodi
present
repres
immunogen
toward
llama
antihuman
antibodi
use
manufactur
process
purifi
particip
anticamelid
antibodi
baselin
develop
antibodi
studi
novel
antimerscov
intraven
immunoglobulin
manufactur
hyperimmun
plasma
transchromosom
cattl
produc
fulli
human
polyclon
igg
use
passiv
immunotherapi
either
immun
plasma
intraven
immunoglobulin
recommend
multipl
sever
emerg
infecti
diseas
sever
season
influenza
pandem
influenza
sever
acut
respiratori
syndrom
mer
ebola
often
limit
collect
suffici
human
plasma
product
albeit
novel
transchromosom
bovin
product
system
importantli
rapid
scalabl
transchromosom
cattl
new
antigenspecif
hightitr
human
intraven
immunoglobulin
gener
within
month
vaccin
avail
therefor
studi
noteworthi
advanc
potenti
therapeut
mer
also
show
potenti
safeti
novel
product
platform
quickli
gener
new
put
drug
candid
emerg
infecti
diseas
result
firstinhuman
phase
studi
suggest
appear
safe
well
toler
singl
dose
mgkg
advers
event
seen
particip
given
larg
compar
given
placebo
event
occur
one
particip
given
low
bicarbon
fatigu
loos
stool
sore
throat
vasovag
reaction
aspart
aminotransferas
increas
correspond
event
placebo
group
vasovag
reaction
occur
studi
drug
administr
low
blood
bicarbon
sore
throat
seem
occur
commonli
higher
dose
cohort
small
number
particip
typic
phase
studi
difficult
discern
certainti
attribut
advers
event
studi
drug
potenti
event
need
investig
close
futur
studi
pharmacokinet
profil
similar
would
expect
human
polyclon
monoclon
antibodi
human
target
critic
ill
popul
clinic
ill
mer
defin
durat
hospit
stay
median
day
iqr
merscov
shed
detect
pcr
median
day
ci
survivor
exceed
day
die
mer
pharmacodynam
profil
neutralis
titr
day
day
mgkg
suggest
good
viral
neutralis
activ
period
exce
clinic
ill
viral
shed
administr
singl
dose
maximum
concentr
occur
initi
sampl
h
end
infus
concentr
remain
detect
end
day
follow
singl
mgkg
mgkg
mgkg
dose
cours
might
differ
infect
patient
light
antibodyviru
bind
subsequ
alter
pharmacokinet
pharmacodynam
efficaci
previous
shown
adenoviru
human
dipeptidyl
peptidas
transduc
balbc
mous
model
transduc
balbc
mice
intranas
infect
merscov
given
h
infect
mice
given
mgkg
assum
g
bodi
weight
mice
h
post
infect
merscov
titr
level
detect
day
p
administ
h
infect
viral
titr
detect
reduc
day
compar
untreat
control
p
given
anim
model
merscov
challeng
replic
human
diseas
effect
relev
model
extrapol
human
efficaci
known
mous
dose
equival
mgkg
equat
human
dose
approxim
mgkg
base
bodi
surfac
area
convers
view
high
mortal
rate
peopl
merscov
infect
difficulti
extrapol
preclin
model
human
diseas
suggest
highest
toler
dose
phase
trial
mgkg
use
initi
human
efficaci
trial
vaccin
use
immunis
transchromosom
cattl
gener
spike
protein
nanoparticl
vaccin
alhasa
strain
belong
clade
b
merscov
pharmacokinet
data
show
high
antibodi
titr
toward
clade
b
strain
previous
shown
neutralis
jordan
erasmu
medic
center
strain
merscov
clade
therefor
anticip
naturalis
capac
current
clade
b
strain
mercov
knowledg
first
studi
show
safeti
toler
pharmacokinet
novel
therapeut
mer
well
new
sourc
fulli
human
igg
produc
transchromosom
cattl
data
attain
studi
suggest
safe
well
toler
potenti
therapeut
exposur
clinic
investig
treatment
mer
warrant
contributor
jhb
jv
es
tl
rtd
respons
initi
studi
design
jhb
jv
rtd
respons
studi
implement
enrol
particip
kr
respons
microneutralis
assay
hw
jaj
es
respons
pharmacokinet
assay
immunogen
assay
jhb
jv
pk
rtd
analys
interpret
data
wrote
first
draft
report
author
opportun
review
data
edit
final
report
hw
jaj
es
financi
interest
sab
biotherapeut
inc
author
declar
compet
interest
